Text Size

Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study

This study has been completed.
Sponsor:
Information provided by:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00227175
First received: September 23, 2005
Last updated: March 31, 2008
Last verified: March 2008
History of Changes
  Purpose

To explore the meaning, causes and treatment of hypertension in eligible patients. In addition the cultural, social, and psychological factors that either facilitate or serve, as barriers to behavioral change will be illuminated in this patient population.


Condition Intervention
Hypertension
 Behavioral: Semi-structured, open ended interview

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Weill Medical College of Cornell University:

Estimated Enrollment: 60
Study Start Date: April 2003
Estimated Study Completion Date: September 2003
Detailed Description:
  1. The first goal is to explore the meaning, causes and treatment of hypertension in eligible patients. In addition the cultural, social, and psychological factors that either facilitate or serve, as barriers to behavioral change will be illuminated in this patient population. Through a series of open-ended questions we will explore and build a better understanding of how hypertensive African American patients view their illness and the difficulties they have in taking their antihypertensive medications as prescribed.
  2. The second goal of the qualitative phase is to use the responses obtained to inform how we should operationalize and tailor the positive affect induction and self-affirmation intervention methods in hypertensive African American patients.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must be self-identified as African-Americans.
  2. All patients must be aged 18 years and older.
  3. All patients must be diagnosed as having hypertension: For this project, hypertension will be defined according to the widely accepted criteria of the 6th Joint National Committee (JNC VI) Guidelines on Prevention, Detection, Evaluation and Treatment of Hypertension, which is a systolic blood pressure > 140 mm hg or a diastolic blood pressure > 90 mm hg or if participants are taking any prescribed antihypertensive medication.
  4. Patients must be able to provide informed consent in English.

Exclusion Criteria:

  1. Patients who refuse to participate
  2. Patients who are unable to provide informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00227175

Locations
United States, New York
The New York Presbyterian Hospital-Weill Medical Center
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Principal Investigator: Carla Boutin-Foster, MD, MS Weill Medical College of Cornell University
Principal Investigator: Gbenga Ogedegbe, MD, MS Columbia University College of Physicians and Surgeons
Study Director: Mary E Charlson, MD Weill Medical College of Cornell University
  More Information

No publications provided by Weill Medical College of Cornell University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Mary E. Charlson, MD, Weill Cornell Medical College
ClinicalTrials.gov Identifier: NCT00227175     History of Changes
Other Study ID Numbers: N01-HC-25196 (0103-659)
Study First Received: September 23, 2005
Last Updated: March 31, 2008
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by Weill Medical College of Cornell University:
African American
Hypertension
Medication adherence
Risk reduction

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013